MX2022001411A - Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5. - Google Patents

Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5.

Info

Publication number
MX2022001411A
MX2022001411A MX2022001411A MX2022001411A MX2022001411A MX 2022001411 A MX2022001411 A MX 2022001411A MX 2022001411 A MX2022001411 A MX 2022001411A MX 2022001411 A MX2022001411 A MX 2022001411A MX 2022001411 A MX2022001411 A MX 2022001411A
Authority
MX
Mexico
Prior art keywords
administration
treating
methods
ccr5 receptor
receptor agents
Prior art date
Application number
MX2022001411A
Other languages
English (en)
Spanish (es)
Inventor
Scott Kelly
Denis Burger
Original Assignee
Cytodyn Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytodyn Inc filed Critical Cytodyn Inc
Publication of MX2022001411A publication Critical patent/MX2022001411A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MX2022001411A 2019-08-02 2020-07-31 Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5. MX2022001411A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882353P 2019-08-02 2019-08-02
US202063047693P 2020-07-02 2020-07-02
PCT/US2020/044616 WO2021026028A1 (en) 2019-08-02 2020-07-31 Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents

Publications (1)

Publication Number Publication Date
MX2022001411A true MX2022001411A (es) 2022-03-25

Family

ID=72193578

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001411A MX2022001411A (es) 2019-08-02 2020-07-31 Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5.

Country Status (9)

Country Link
US (1) US20220298249A1 (https=)
EP (1) EP4007603A1 (https=)
JP (1) JP2022542524A (https=)
CN (1) CN114502594A (https=)
AU (1) AU2020324948A1 (https=)
BR (1) BR112022001037A2 (https=)
CA (1) CA3146474A1 (https=)
MX (1) MX2022001411A (https=)
WO (1) WO2021026028A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532019A (ja) * 2020-06-23 2023-07-26 マドン アドバイザーズ エルエルシー 抗ｃｃｒ５モノクローナル抗体ベースの組成物および方法
WO2025250666A1 (en) * 2024-05-29 2025-12-04 Cytodyn, Inc. Methods of treating cancer and inflammation-related diseases with leronlimab

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
CA2616189C (en) 2005-07-22 2019-03-26 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients
MX2008014296A (es) * 2006-06-12 2009-03-06 Pfizer Prod Inc Antagonista de ccr5 para mejorar la restitucion inmunitaria y tratar la infeccion oportunista en pacientes con vih.
CA2939464A1 (en) * 2014-02-18 2015-08-27 Cytodyn Inc. Use of anti-ccr5 antibodies in graft versus host disease
CN107847514A (zh) 2015-06-23 2018-03-27 西托戴恩股份有限公司 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变
US20190016810A1 (en) * 2017-05-11 2019-01-17 Cytodyn Inc. Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents

Also Published As

Publication number Publication date
BR112022001037A2 (pt) 2022-06-07
EP4007603A1 (en) 2022-06-08
JP2022542524A (ja) 2022-10-04
WO2021026028A1 (en) 2021-02-11
CA3146474A1 (en) 2021-02-11
AU2020324948A1 (en) 2022-02-17
CN114502594A (zh) 2022-05-13
US20220298249A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
MX2024009727A (es) Terapias de combinacion.
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
PH12021550020A1 (en) High-affinity, isoform-selective tgf#1 inhibitors and use thereof
MY191423A (en) Binding molecules specific for cd73 and uses thereof
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
MX2021007350A (es) Terapia combinada de cd70 y venetoclax, un inhibidor de bcl-2, para tratar la leucemia mieloide aguda.
PH12022550509A1 (en) Anti-cd73 antibodies
PH12018500642A1 (en) Anti-garp antibody
MX2024007724A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
ZA202202363B (en) Antibodies against ilt2 and use thereof
EP4589014A3 (en) Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden
MX2023002554A (es) Anticuerpos anti-il-1r3 humanizados.
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MX2011013424A (es) Metodo de tratamiento del cancer con antagonista dll4 y agente quimioterapeutico.
MX2013009732A (es) Terapias de combinacion comprendiendo agentes anti-erbb3.
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
EA202090791A1 (ru) Агонистические антитела против cd40
ZA202302392B (en) Antibodies against ilt2 and use thereof
ZA201907754B (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
MX2023004342A (es) Politerapia de antagonistas de union al eje de pd-1 e inhibidores de lrrk2.
WO2019168897A3 (en) Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents